Application of cytokeratin 19 combined with squamous cell carcinoma antigen detection for early diagnosis and curative effect evaluation in patients with cervical cancer

Objective To explore the clinical value of cytokeratin 19(CYFRA21-1)combined with squamous cell carcinoma antigen(SCCAg)detection in early diagnosis and curative effect evaluation in patients with cervical cancer.Methods A total of 97 patients with cervical cancer and 45 patients with cervical epithelial atypical hyperplasia(CIN group)in Dazhou Military Hospital from Aug.2010 to Aug.2013 were enrolled in this study.Other 50 cases of healthy women,conducted physical examination,were enrolled in control group.The levels of CYFRA21-1and SCCAg were detected by electrochemiluminescence immunoassay method and compared among the three groups.Results Compared with the control and CIN group,the serum CYFRA21-1and SCCAg levels in cervical cancer patients were significantly elevated(P0.05).The levels and positive detectable rate of serum CYFRA21-1and SCCAg were significant higher in stageⅢ-Ⅳ of cervical cancer than those in stage Ⅰ-Ⅱ(P0.05).The sensitivity of combined detection was increased to 62.47%.The serum CYFRA21-1and SCCAg levels were significantly decreased in patients with cervical cancer after chemotherapy,compared with those before chemotherapy(P0.05).Conclusion Combination of serum CYFRA21-1and SCCAg detection might be with important reference value for the early diagnosis and curative effect evaluation in patients with cervical cancer.